iShares MSCI Hong Kong ETF vs Novavax Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.43, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| EWH | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $11.19 |
52-Week Low | $20.66 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
EWH, a US-listed stock tracking Hong Kong equities, trades at $22.465, down 1.47% over 24 hours. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The stock faces resistance at $23 and support at $22. Recent news highlights the Hang Seng Index's rebound, driven by technology sector gains, with EWH positioned to benefit from this momentum.
The outlook for EWH hinges on Hong Kong market performance, with potential upside from continued tech recovery and Asian market stability. Risks include regional volatility and macroeconomic pressures. Analysts show mixed sentiment, balancing technical bearishness with fundamental opportunities in the rebounding index.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →